Elisabeth Singer

Ms. Elisabeth Singer

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2019 in Cells
Verified
Journal Article
Open access
PDF file
LYLibo Yu-Taeger
Libo Yu-Taeger
JSJanice Stricker-Shaver
Janice Stricker-Shaver
KAKatrin Arnold
Katrin Arnold
PBPatrycja Bambynek-Dziuk
Patrycja Bambynek-Dziuk
ANArianna Novati
Arianna Novati
Huu Phuc NguyenHuu Phuc Nguyen
Huu Phuc Nguyen
Intrastriatal administration of mesenchymal stem cells (MSCs) has shown beneficial effects in rodent models of Huntington disease (HD). However, the invasive nature of surgical procedure and its potential to trigger the host immune response may limit its clinical use. Hence, we sought to evaluate the non-invasive intranasal administration (INA) of MSC delivery as an effective alternative route in HD. GFP-expressing MSCs derived from bone marrow were intranasally administered to 4-week-old R6/2 HD transgenic mice. MSCs were detected in the olfactory bulb, midbrain and striatum five days post-delivery. Compared to phosphate-buffered saline (PBS)-treated littermates, MSC-treated R6/2 mice showed an increased survival rate and attenuated circadian activity disruption assessed by locomotor activity. MSCs increased the protein expression of DARPP-32 and tyrosine hydroxylase (TH) and downregulated gene expression of inflammatory modulators in the brain 7.5 weeks after INA. While vehicle treated R6/2 mice displayed decreased Iba1 expression and altered microglial morphology in comparison to the wild type littermates, MSCs restored both, Iba1 level and the thickness of microglial processes in the striatum of R6/2 mice. Our results demonstrate significantly ameliorated phenotypes of R6/2 mice after MSCs administration via INA, suggesting this method as an effective delivering route of cells to the brain for HD therapy.

14 February 2019 in BioMed Research International
Verified
Journal Article
Open access
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
PSPriscila Pereira Sena
Priscila Pereira Sena
ESElisabeth Singer
Elisabeth Singer
HNHuu Phuc Nguyen
Huu Phuc Nguyen
Proteolytic machineries execute vital cellular functions and their disturbances are implicated in diverse medical conditions, including neurodegenerative diseases. Interestingly, calpains, a class of Ca2+-dependent regulatory proteases, can modulate the degradational system of autophagy by cleaving proteins involved in this pathway. Moreover, both machineries are common players in many molecular pathomechanisms and have been targeted individually or together, as a therapeutic strategy in experimental setups. In this review, we briefly introduce calpains and autophagy, with their roles in health and disease, and focus on their direct pathologically relevant interplay in neurodegeneration and beyond. The modulation of calpain activity may comprise a promising treatment approach to attenuate the deregulation of these two essential mechanisms.

4 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ESElisabeth Singer
Elisabeth Singer
CWCarolin Walter
Carolin Walter
Jonasz Jeremiasz WeberJonasz Jeremiasz Weber
Jonasz Jeremiasz Weber
AKAnn-Christin Krahl
Ann-Christin Krahl
UMUlrike A. Mau-Holzmann
Ulrike A. Mau-Holzmann
Huu Phuc NguyenHuu Phuc Nguyen
Huu Phuc Nguyen
Huntington disease is a fatal neurodegenerative disorder caused by a CAG repeat expansion in the gene encoding the huntingtin protein. Expression of the mutant protein disrupts various intracellular pathways and impairs overall cell function. In particular striatal neurons seem to be most vulnerable to mutant huntingtin-related changes. A well-known and commonly used model to study molecular aspects of Huntington disease are the striatum-derived STHdh cell lines generated from wild type and huntingtin knock-in mouse embryos. However, obvious morphological differences between wild type and mutant cell lines exist, which have rarely been described and might not have always been considered when designing experiments or interpreting results. Here, we demonstrate that STHdh cell lines display differences in cell size, proliferation rate and chromosomal content. While the chromosomal divergence is considered to be a result of the cells’ tumour characteristics, differences in size and proliferation, however, were confirmed in a second non-immortalized Huntington disease cell model. Importantly, our results further suggest that the reported phenotypes can confound other study outcomes and lead to false conclusions. Thus, careful experimental design and data analysis are advised when using these cell models.

1 January 2020 in Neuropharmacology
Verified
Journal Article
Closed access
ESElisabeth Singer
Elisabeth Singer
CWCarolin Walter
Carolin Walter
DFDoriano Fabbro
Doriano Fabbro
DRDenise Rageot
Denise Rageot
FBFlorent Beaufils
Florent Beaufils
Huu Phuc NguyenHuu Phuc Nguyen
Huu Phuc Nguyen

Verified
Journal Article
Open access
PDF file
ANAnna Niewiadomska-Cimicka
Anna Niewiadomska-Cimicka
LFLorraine Fievet
Lorraine Fievet
MSMagdalena Surdyka
Magdalena Surdyka
EJEwelina Jesion
Ewelina Jesion
CKCéline Keime
Céline Keime
YTYvon Trottier
Yvon Trottier
Polyglutamine (polyQ)-encoding CAG repeat expansions represent a common disease-causing mutation responsible for several dominant spinocerebellar ataxias (SCAs). PolyQ-expanded SCA proteins are toxic for cerebellar neurons, with Purkinje cells (PCs) being the most vulnerable. RNA interference (RNAi) reagents targeting transcripts with expanded CAG reduce the level of various mutant SCA proteins in an allele-selective manner in vitro and represent promising universal tools for treating multiple CAG/polyQ SCAs. However, it remains unclear whether the therapeutic targeting of CAG expansion can be achieved in vivo and if it can ameliorate cerebellar functions. Here, using a mouse model of SCA7 expressing a mutant Atxn7 allele with 140 CAGs, we examined the efficacy of short hairpin RNAs (shRNAs) targeting CAG repeats expressed from PHP.eB adeno-associated virus vectors (AAVs), which were introduced into the brain via intravascular injection. We demonstrated that shRNAs carrying various mismatches with the CAG target sequence reduced the level of polyQ-expanded ATXN7 in the cerebellum, albeit with varying degrees of allele selectivity and safety profile. An shRNA named A4 potently reduced the level of polyQ-expanded ATXN7, with no effect on normal ATXN7 levels and no adverse side effects. Furthermore, A4 shRNA treatment improved a range of motor and behavioral parameters 23 weeks after AAV injection and attenuated the disease burden of PCs by preventing the downregulation of several PC-type-specific genes. Our results show the feasibility of the selective targeting of CAG expansion in the cerebellum using a blood–brain barrier-permeable vector to attenuate the disease phenotype in an SCA mouse model. Our study represents a significant advancement in developing CAG-targeting strategies as a potential therapy for SCA7 and possibly other CAG/polyQ SCAs.

1 May 2019 in Neurobiology of Disease
Verified
Journal Article
Closed access
MLM. Lessard-Beaudoin
M. Lessard-Beaudoin
LYLibo Yu-Taeger
Libo Yu-Taeger
MLM. Laroche
M. Laroche
ESElisabeth Singer
Elisabeth Singer
ORO. Riess
O. Riess
RGR.K. Graham
R.K. Graham